ERBB2 and breast carcinoma: Poly(ADP-ribose) polymerase (PARP) plays a major role in single-strand DNA repair, and PARP inhibitors have demonstrated antitumor activity in HER2-negative metastatic breast cancer patients, associated with BRCA1/2 germline mutations.